Table 4.
Tumor pCR rates in patient subgroups
| Subset | XEC (%) | FEC (%) | P-value* | Interaction P |
|---|---|---|---|---|
| Age (years) | ||||
| <50 | 4 (10) | 1 (2) | 0.184 | 0.873 |
| ≥50 | 7 (37) | 3 (13) | 0.143 | |
| T-stage | ||||
| <5 cm | 7 (27) | 3 (10) | 0.160 | 0.795 |
| ≥5 cm | 4 (11) | 1 (3) | 0.183 | |
| N-stage | ||||
| N1 | 6 (21) | 3 (9) | 0.170 | 0.583 |
| N2/N3 | 5 (15) | 1 (3) | 0.101 | |
| HR | ||||
| Positive | 4 (10) | 2 (4) | 0.409 | 0.529 |
| Negative | 7 (32) | 2 (8) | 0.063 | |
| HER2 | ||||
| Positive | 3 (18) | 1 (5) | 0.307 | 0.870 |
| Negative/unknown | 8 (18) | 3 (6) | 0.072 | |
| Molecular type | ||||
| Triple negative | 10 (83) | 2 (22) | 0.009 | 0.028 |
| Non-triple negative | 1 (2) | 2 (3) | 1.000 | |
| Clinical response | ||||
| CR | 5 (42) | 1 (20) | 0.600 | 0.995 |
| PR/SD/PD | 6 (12) | 3 (5) | 0.307 | |
Note:
*
P-value by chi-square test or Fisher’s exact test when the cell expectation was less than six.
Abbreviations: CR, complete response; FEC, 5-FU/epirubicin/cyclophosphamide; 5-FU, 5-fluorouracil; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; pCR, pathological complete response; PD, progressive disease; PR, partial response; SD, stable disease; XEC, capecitabine/epirubicin/cyclophosphamide.